Status:

RECRUITING

Study of the Blood and Skin Immunological Profile of Patients With Recessive Dystrophic Epidermolysis Bullosa: in Vivo Analysis and the Impact of Placental Stem Cells in Vitro

Lead Sponsor:

Assistance Publique - Hôpitaux de Paris

Conditions:

Epidermolysis Bullosa Dystrophica

Eligibility:

All Genders

18-80 years

Brief Summary

Patients with recessive dystrophic epidermolysis bullosa (RDEB) suffer from acute and chronic post-bullous wounds along with impaired skin healing. These issues are attributed not only to mucocutaneou...

Eligibility Criteria

Inclusion

  • EBDR patients :
  • Patients aged 18 to 80 years old
  • Clinically, histologically, and/or genetically confirmed intermediate, reversed or generalized, moderate to severe EBDR
  • Healthy controls :
  • Adults aged 18 to 80 years old
  • PBMC healthy donors: subjects who have donated blood to the EFS according to the indication criteria who have consented to the use of their samples for research purposes.
  • Healthy skin biopsy donors: subjects undergoing abdominoplasty scheduled in plastic surgery and who have given their consent for the collection of a skin biopsy from post-operative abdominoplasty skin remnants.
  • Healthy donors of bandages soiled with exudates from cutaneous wounds: subject consulting a plastic surgery department as part of their usual post-operative follow-up, who have given their consent for the collection of one of their dressings during their usual during their usual renewal.
  • For all subjects :
  • Free, informed, written consent, signed by the person and the investigator no later than the day of inclusion and before any examination carried out as part of the study.
  • Person affiliated or benefiting from a social security scheme

Exclusion

  • EBDR patients :
  • EBH with no definite diagnosis or other than EBDR intermediate, reversed or generalized
  • Systemic anti-inflammatory or immunosuppressive therapy for less than one month
  • Refusal of skin biopsy
  • Healthy controls :
  • Acute or chronic systemic or cutaneous inflammatory disease at the time of sampling
  • Current immunosuppressive anti-inflammatory treatment in the month prior to sampling
  • For all subjects:
  • Persons under guardianship or curatorship, or deprived of their liberty by judicial or administrative decision
  • Patients receiving State Medical Aid
  • Pregnant or breast-feeding women

Key Trial Info

Start Date :

April 15 2024

Trial Type :

OBSERVATIONAL

Allocation :

ESTIMATED

End Date :

April 15 2025

Estimated Enrollment :

30 Patients enrolled

Trial Details

Trial ID

NCT06177353

Start Date

April 15 2024

End Date

April 15 2025

Last Update

July 17 2024

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Hopital Saint Louis - Service de chirurgie plastique reconstructrice et esthétique et traitement chirurgical des brûlés

Paris, France

2

Hopital Saint Louis - service dermatologie

Paris, France